 |
|
IND Meeting Reports: 2008-2011
|
| ID |
Site |
Study Title |
Status |
|
IND.207 |
Phase II |
A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma
MORE... |
Open |
|
IND.206 |
Phase II |
A Phase II Study of Sunitinib or Temsirolimus in Patients with Advanced Rare Tumours
MORE... |
Open |
|
IND.205 |
Phase II |
A Phase II Study of PX-866 in Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
MORE... |
Open |
|
IND.204 |
Phase II |
A Phase II Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
MORE... |
On Hold |
|
IND.203 |
Phase I |
A Phase I Study of SB939 in Pediatric Patients with Refractory Solid Tumours and Leukemia
MORE... |
Closed |
|
IND.202 |
Phase II |
A Randomized Phase II Study of Interleukin-21 (rIL-21) versus Dacarbazine (DTIC) in
Patients with Metastatic or Recurrent Melanoma
MORE... |
Open |
|
IND.200 |
Phase II |
A Phase II Study of SB939 in Patients with Translocation-Associated Recurrent/Metastatic Sarcomas
MORE... |
Closed |
|
IND.199 |
Phase II |
A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients with Recurrent,
Unresectable, Locally Advanced or Metastatic Carcimona of the Cervix
MORE... |
Closed |
|
IND.198 |
Phase I/II |
A Phase I/II Study of Foretinib in Combination with Lapatinib in Patients with Human Epidermal
Growth Factor Receptor (HER2) Over-Expressing Metastatic Breast Cancer
MORE... |
On Hold |
|
IND.197 |
Phase II |
A Phase II Study of Foretinib in Patients with Estrogen Receptor (ER), Progesterone Receptor (PR) and
Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer
MORE... |
On Hold |
|
IND.196 |
Phase I/II |
A Phase I/II Study of Foretinib in Patients with Previously Treated Non-Small Cell Lung
Cancer Receiving Standard Erlotinib Therapy
MORE... |
On Hold |
|
IND.195 |
Phase II |
A Phase II Study of SB939 in Patients with Recurrent or Metastatic Castration Resistant Prostate Cancer
MORE... |
Closed |
|
IND.193 |
Phase II |
A Phase II Study of AT7519M, A CDK Inhibitor in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia
MORE... |
Planned |
|
IND.192 |
Phase II |
A Phase II Study of Ridaforolimus in Patients with Metastatic and/or Locally Advanced
Recurrent Endometrial Cancer
MORE... |
Closed |
|
IND.191 |
Phase II |
A Phase II Study of AT9283 in Patients with Relapsed or Refractory Multiple Myeloma
MORE... |
Open |
|
IND.190 |
Phase I/II |
A Phase I-II Trial of MK-0646, a Monoclonal Antibody Against Insulin-Like Growth Factor-1
Receptor in Combination with Etoposide and Cisplatin in Extensive Stage Small Cell Lung Cancer
MORE... |
Closed |
|
IND.189 |
Phase II |
A Phase II Study of Interlukin-21 (Il-21) in Patients with Metastatic or Recurrent Malignant
Melanoma
MORE... |
Closed |
|
IND.188 |
Phase I |
A Clinical and Pharmacokinetic Study of Sb939 in Patients with Advanced Cancer
MORE... |
Permanently Closed |
|
IND.187 |
Phase I |
A Phase I Study Of AZD2281 In Combination With Irinotecan In Patients With Locally Advanced
or Metastatic Incurable Colorectal Cancer
MORE... |
On Hold |
|
IND.186 |
Phase I/II |
A Phase I/II Study of Sorafenib (BAY 43-9006) In Combination With Low Dose ARA-C (Cytarabine)
In Elderly Patients With AML Or High-Risk MDS
MORE... |
Closed |
|
IND.185 |
Gynecologic |
A Phase II Study of Sunitinib (SU11248; NSC 736511) in Patients with Recurrent Epithelial
Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
MORE... |
Permanently Closed |
|
IND.184 |
Gynecologic |
A Phase II Study of Sunitinib, an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients
with Unresectable, Locally Advanced or Metastatic Cervical Carcinoma
MORE... |
Permanently Closed |
|
IND.183 |
Phase II |
A Phase II Study of Sunitinib in Patients with Advanced Malignant Pleural Mesothelioma
MORE... |
Permanently Closed |
|
IND.182 |
Hematologic |
A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019), an Oral Multi-Targeted Tyrosine
Kinase Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
MORE... |
Permanently Closed |
|
IND.181 |
Phase I |
NCIC CTG Phase I Study of AT9283 Given as a 24 Hour Infusion on Days 1 and 8 Every Three Weeks
in Patients with Advanced Incurable Malignancy
MORE... |
Permanently Closed |
|
IND.179 |
Phase I |
A Phase I Study of CCI-779 in Combination with Carboplatin and Paclitaxel in Patients with
Advanced Solid Tumours
MORE... |
Permanently Closed |
|
IND.178 |
Phase I |
A Phase I Dose-Escalation Study Of JX-963 (Thymidine Kinase/Vaccinia Growth Factor Gene-Deleted
Vaccinia Virus Plus GM-CSF) In Patients With Advanced Incurable Solid Tumours
MORE... |
Closed |
|
IND.177 |
Phase I |
A Phase I Study of AT7519M Given Twice Weekly in Patients with Advanced
Incurable Malignancy
MORE... |
Closed |
|
IND.175 |
Phase I |
A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination with
Selected Standard Chemotherapy Regimens (CT) in Patients with Advanced Incurable Non-Small Cell Lung Cancer (NSCLC)
or Colorectal Cancer
MORE... |
Permanently Closed |
|
IND.173 |
Phase I/II |
A Phase I/II Study of AZD0530 in Combination with Gemcitabine in Patients with
Advanced Pancreatic Cancer
MORE... |
Permanently Closed |
|
IND.172 |
Hematologic |
Phase II Study of Bortezomib and Gemcitabine in Patients with Relapsed Mantle Cell Lymphoma
MORE... |
Permanently Closed |
|
IND.171 |
Phase I |
A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination with
Standard Chemotherapy Regimens (CT) in Patients with Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or
Colorectal Cancer or Other Tumour Types Suitable for Treatment with Capecitabine
MORE... |
Permanently Closed |
|
IND.170 |
Phase I/II |
A Phase I/II Study of GW572016 in Patients with Recurrent Malignant Glioma
MORE... |
Permanently Closed |
|
IND.169 |
Melanoma |
This is a Non-Randomized, Non-Blinded Multicentre Phase II Study of SB-715992 in Previously
Untreated Patients with Metastatic or Recurrent Malignant Melanoma
MORE... |
Permanently Closed |
|
IND.168 |
Phase II |
SB-715992 (NSC 727990) in Patients with Locally Advanced, Recurrent or Metastatic
Hepatocellular Carcinoma
MORE... |
Permanently Closed |
|
IND.167 |
Genito-Urinary |
Phase II Study of BAY 43-9006 (NSC 724772) in Patients with Hormone Refractory Prostate Cancer
MORE... |
Permanently Closed |
|
IND.166B |
Phase I |
This is a Multi-Centre, Open-Label, Dose-Escalating Phase I Clinical Trial of AEG35156 in
Combination with Docetaxel in Patients with Solid Tumours
MORE... |
Permanently Closed |
|
IND.166 |
Phase I |
This is a Multi-Centre, Open-Label, Dose-Escalating Phase I Clinical Trial of AEG35156 in
Combination with Docetaxel in Patients with Solid Tumours
MORE... |
Permanently Closed |
|
IND.165 |
Genito-Urinary |
A Randomized Phase II Study of OGX-011 in Combination with Docetaxel and Prednisone or
Docetaxel and Prednisone Alone in Patients with Metastatic Hormone Refractory Prostate Cancer
MORE... |
Permanently Closed |
|
IND.164 |
Breast |
A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in
Combination with Docetaxel in Advanced Breast Cancer
MORE... |
Permanently Closed |
|
IND.163 |
Breast |
A Randomized Phase II Study of Two Different Schedules of RAD001C in Patients with
Recurrent/Metastatic Breast Cancer
MORE... |
Permanently Closed |
|
IND.162 |
Phase I |
A Phase I Study of Temozolomide and RAD001C in Patients with Malignant Glioma
MORE... |
Permanently Closed |
|
IND.160 |
Gynecologic |
A Phase II Study Of CCI-779 in Patients with Metastatic and/or Locally Advanced Recurrent
Endometrial Cancer
MORE... |
Closed |
